Status:
UNKNOWN
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
Lead Sponsor:
National Taiwan University Hospital Hsin-Chu Branch
Conditions:
Hemodialysis Access Failure
Eligibility:
All Genders
20-99 years
Phase:
PHASE4
Brief Summary
Taiwan was among the countries with high prevalence of end stage renal disease (ESRD), and more than 90% of ESRD patients in Taiwan received hemodialysis. Thrombosis are the most common complications ...
Eligibility Criteria
Inclusion
- Age 20-99 years old
- End stage renal disease, patients on maintenance hemodialysis for at least one month
- Dialysis vascular access thrombosis, documented by angiograph, and thrombosis was salvaged by endovascular or surgical procedures successfully
Exclusion
- History of intracranial hemorrhage
- Major bleeding in recent 3 months, which defined as Bleeding Academic Research Consortium (BARC) 2 criteria
- Concomitant use of dual antiplatelet agent (aspirin and clopidogrel)
- Concomitant use of ticagrelor
- Concomitant use of warfarin
- Planned to receive surgery in recent 3 months
- Planned to receive coronary stents in recent 3 months
- Hemoglobin \< 7.0 g/dL or Platelet count \< 80 K/uL
- Moderate or severe liver dysfunction, defined as Child-Pugh score \> 6
- Patient received bioprosthetic or mechanical heart valve
- Cannot signed informed consent
Key Trial Info
Start Date :
March 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 14 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04489849
Start Date
March 14 2020
End Date
June 14 2022
Last Update
July 28 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital HsinChu branch
Hsinchu, Taiwan, 300
2
National Taiwan University Hospital,HsinChu branch
Hsinchu, Taiwan, 300